Logo image of MLSS

MILESTONE SCIENTIFIC INC (MLSS) Stock Fundamental Analysis

NYSEARCA:MLSS - NYSE Arca - US59935P2092 - Common Stock - Currency: USD

1.04  -0.05 (-4.59%)

Fundamental Rating

3

MLSS gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 189 industry peers in the Health Care Equipment & Supplies industry. MLSS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. MLSS is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year MLSS has reported negative net income.
MLSS had a negative operating cash flow in the past year.
MLSS had negative earnings in each of the past 5 years.
MLSS had a negative operating cash flow in each of the past 5 years.
MLSS Yearly Net Income VS EBIT VS OCF VS FCFMLSS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -2M -4M -6M -8M

1.2 Ratios

MLSS has a worse Return On Assets (-41.31%) than 61.70% of its industry peers.
The Return On Equity of MLSS (-63.93%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -41.31%
ROE -63.93%
ROIC N/A
ROA(3y)-52.98%
ROA(5y)-62.22%
ROE(3y)-71.09%
ROE(5y)-140.19%
ROIC(3y)N/A
ROIC(5y)N/A
MLSS Yearly ROA, ROE, ROICMLSS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -100 -200 -300 -400

1.3 Margins

MLSS's Gross Margin of 72.48% is amongst the best of the industry. MLSS outperforms 82.98% of its industry peers.
In the last couple of years the Gross Margin of MLSS has grown nicely.
The Profit Margin and Operating Margin are not available for MLSS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 72.48%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.27%
GM growth 5Y8.46%
MLSS Yearly Profit, Operating, Gross MarginsMLSS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50 -50 -100

More info and screens

5

2. Health

2.1 Basic Checks

MLSS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MLSS has been increased compared to 1 year ago.
Compared to 5 years ago, MLSS has more shares outstanding
The debt/assets ratio for MLSS has been reduced compared to a year ago.
MLSS Yearly Shares OutstandingMLSS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M
MLSS Yearly Total Debt VS Total AssetsMLSS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M

2.2 Solvency

Based on the Altman-Z score of -3.93, we must say that MLSS is in the distress zone and has some risk of bankruptcy.
MLSS has a worse Altman-Z score (-3.93) than 67.02% of its industry peers.
MLSS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.93
ROIC/WACCN/A
WACC9.06%
MLSS Yearly LT Debt VS Equity VS FCFMLSS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 5M -5M 10M 15M

2.3 Liquidity

MLSS has a Current Ratio of 2.85. This indicates that MLSS is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of MLSS (2.85) is comparable to the rest of the industry.
MLSS has a Quick Ratio of 1.59. This is a normal value and indicates that MLSS is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of MLSS (1.59) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.85
Quick Ratio 1.59
MLSS Yearly Current Assets VS Current LiabilitesMLSS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 40.25% over the past year.
MLSS shows a decrease in Revenue. In the last year, the revenue decreased by -9.51%.
The Revenue has been growing slightly by 0.43% on average over the past years.
EPS 1Y (TTM)40.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.65%
Revenue 1Y (TTM)-9.51%
Revenue growth 3Y21.79%
Revenue growth 5Y0.43%
Sales Q2Q%22.03%

3.2 Future

MLSS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.47% yearly.
The Revenue is expected to grow by 7.61% on average over the next years.
EPS Next Y37.5%
EPS Next 2Y19.9%
EPS Next 3Y14.47%
EPS Next 5YN/A
Revenue Next Year-12.34%
Revenue Next 2Y1.69%
Revenue Next 3Y7.61%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
MLSS Yearly Revenue VS EstimatesMLSS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2M 4M 6M 8M 10M
MLSS Yearly EPS VS EstimatesMLSS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -0.05 -0.1 -0.15 -0.2 -0.25

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MLSS. In the last year negative earnings were reported.
Also next year MLSS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MLSS Price Earnings VS Forward Price EarningsMLSS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MLSS Per share dataMLSS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.05 -0.05 0.1

4.3 Compensation for Growth

MLSS's earnings are expected to grow with 14.47% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.9%
EPS Next 3Y14.47%

More info and screens

0

5. Dividend

5.1 Amount

MLSS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MILESTONE SCIENTIFIC INC

NYSEARCA:MLSS (2/21/2025, 8:04:00 PM)

1.04

-0.05 (-4.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-14 2024-11-14/amc
Earnings (Next)03-27 2025-03-27/amc
Inst Owners5.7%
Inst Owner Change-98.72%
Ins Owners6.89%
Ins Owner Change2.13%
Market Cap81.01M
Analysts82.5
Price Target2.17 (108.65%)
Short Float %0.22%
Short Ratio0.72
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-96.08%
Min EPS beat(2)-96.08%
Max EPS beat(2)-96.08%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-16.8%
Min Revenue beat(2)-27.95%
Max Revenue beat(2)-5.64%
Revenue beat(4)0
Avg Revenue beat(4)-18.2%
Min Revenue beat(4)-30.44%
Max Revenue beat(4)-5.64%
Revenue beat(8)2
Avg Revenue beat(8)-9.78%
Revenue beat(12)5
Avg Revenue beat(12)-8%
Revenue beat(16)7
Avg Revenue beat(16)-5.98%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-25%
EPS NY rev (3m)-25%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-5.45%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-3.19%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 9.13
P/FCF N/A
P/OCF N/A
P/B 11.22
P/tB 11.46
EV/EBITDA N/A
EPS(TTM)-0.06
EYN/A
EPS(NY)-0.05
Fwd EYN/A
FCF(TTM)-0.03
FCFYN/A
OCF(TTM)-0.03
OCFYN/A
SpS0.11
BVpS0.09
TBVpS0.09
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -41.31%
ROE -63.93%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 72.48%
FCFM N/A
ROA(3y)-52.98%
ROA(5y)-62.22%
ROE(3y)-71.09%
ROE(5y)-140.19%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.27%
GM growth 5Y8.46%
F-Score4
Asset Turnover0.79
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 27.96%
Cap/Sales 0.13%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.85
Quick Ratio 1.59
Altman-Z -3.93
F-Score4
WACC9.06%
ROIC/WACCN/A
Cap/Depr(3y)17.69%
Cap/Depr(5y)17.06%
Cap/Sales(3y)0.12%
Cap/Sales(5y)0.17%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)40.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.65%
EPS Next Y37.5%
EPS Next 2Y19.9%
EPS Next 3Y14.47%
EPS Next 5YN/A
Revenue 1Y (TTM)-9.51%
Revenue growth 3Y21.79%
Revenue growth 5Y0.43%
Sales Q2Q%22.03%
Revenue Next Year-12.34%
Revenue Next 2Y1.69%
Revenue Next 3Y7.61%
Revenue Next 5YN/A
EBIT growth 1Y6.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y50.07%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y50.29%
OCF growth 3YN/A
OCF growth 5YN/A